Amikacin levels in bronchial secretions of 10 pneumonia patients with respiratory support treated once daily versus twice daily

Antimicrob Agents Chemother. 1995 Jan;39(1):264-7. doi: 10.1128/AAC.39.1.264.

Abstract

In this study, concentrations of amikacin in blood and bronchial secretions of 10 patients with mechanical ventilation for acute respiratory failure due to pneumonia were measured. One-half of the patients received amikacin twice daily, and the others received once-daily administration. Concentrations in bronchial secretions of the patients treated twice daily ranged from 3 to 4 mg/liter, i.e., they were similar to those in previously published reports. Peak concentrations in bronchial secretions occurred between 3 and 4 h after the onset of infusion, and they reached 4.8 +/- 2.6 mg/liter on day 1 and 4.0 +/- 2.7 mg/liter on day 3. For the patients treated with amikacin once daily, concentrations in bronchial secretions were more than twofold higher, above 8 mg/liter for 12 h. Peak concentrations in bronchial secretions occurred between 3 and 4 h after the onset of infusion and reached 13.6 +/- 9.3 mg/liter on day 1 and 10.4 +/- 3.5 mg/liter on day 3. These concentrations are higher than the MICs for less sensitive bacterial strains, such as Acinetobacter spp. and Pseudomonas aeruginosa.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Amikacin / administration & dosage
  • Amikacin / pharmacokinetics*
  • Bronchi / metabolism*
  • Drug Administration Schedule
  • Female
  • Humans
  • Male
  • Middle Aged
  • Pneumonia, Bacterial / complications*
  • Pneumonia, Bacterial / metabolism
  • Respiration, Artificial
  • Respiratory Insufficiency / etiology*
  • Respiratory Insufficiency / metabolism
  • Respiratory Insufficiency / therapy

Substances

  • Amikacin